Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 11

1.

The impact of cardiac resynchronization therapy on routine laboratory parameters.

Boros AM, Perge P, Nagy KV, Apor A, Bagyura Z, Zima E, Molnár L, Tahin T, Becker D, Gellér L, Merkely B, Széplaki G.

Interv Med Appl Sci. 2017 Mar;9(1):1-8. doi: 10.1556/1646.9.2017.1.01.

2.

Impact of Hemoglobin Levels and Anemia on Mortality in Acute Stroke: Analysis of UK Regional Registry Data, Systematic Review, and Meta-Analysis.

Barlas RS, Honney K, Loke YK, McCall SJ, Bettencourt-Silva JH, Clark AB, Bowles KM, Metcalf AK, Mamas MA, Potter JF, Myint PK.

J Am Heart Assoc. 2016 Aug 17;5(8). pii: e003019. doi: 10.1161/JAHA.115.003019.

3.

Measurement of the Red Blood Cell Distribution Width Improves the Risk Prediction in Cardiac Resynchronization Therapy.

Boros AM, Perge P, Jenei Z, Karády J, Zima E, Molnár L, Becker D, Gellér L, Prohászka Z, Merkely B, Széplaki G.

Dis Markers. 2016;2016:7304538. doi: 10.1155/2016/7304538. Epub 2016 Jan 19.

4.

Renal anemia - risk factor for chronic kidney disease.

Cană-Ruiu D, Moţa E, Istrate N, Văduva C, Trican E.

Curr Health Sci J. 2013 Oct;39(4):214-7. Epub 2013 Oct 10.

5.

Comparison between short- and long-acting erythropoiesis-stimulating agents in hemodialysis patients: target hemoglobin, variability, and outcome.

Bernieh B, Abouchacra S, Boobes Y, Al Hakim MR, Nagelkerke N, Chaaban A, Ahmed M, Hussain Q, Jack HE, Abayechi F, Khan I, Gebran N.

Int Urol Nephrol. 2014 Feb;46(2):453-9. doi: 10.1007/s11255-013-0640-7. Epub 2014 Jan 22.

6.

Intravenous C.E.R.A. maintains stable haemoglobin levels in patients on dialysis previously treated with darbepoetin alfa: results from STRIATA, a randomized phase III study.

Canaud B, Mingardi G, Braun J, Aljama P, Kerr PG, Locatelli F, Villa G, Van Vlem B, McMahon AW, Kerloëguen C, Beyer U; STRIATA Study Investigators.

Nephrol Dial Transplant. 2008 Nov;23(11):3654-61. doi: 10.1093/ndt/gfn320. Epub 2008 Jun 27.

7.

Recombinant human epoetin beta in the treatment of renal anemia.

Locatelli F, Pozzoni P, Vecchio LD.

Ther Clin Risk Manag. 2007 Jun;3(3):433-9.

8.

Chronic kidney disease and its complications.

Thomas R, Kanso A, Sedor JR.

Prim Care. 2008 Jun;35(2):329-44, vii. doi: 10.1016/j.pop.2008.01.008. Review.

9.

The role of anemia management in improving outcomes for African-Americans with chronic kidney disease.

Lea JP, Norris K, Agodoa L.

Am J Nephrol. 2008;28(5):732-43. doi: 10.1159/000127981. Epub 2008 Apr 24. Review.

11.

Anemia, costs and mortality in chronic obstructive pulmonary disease.

Halpern MT, Zilberberg MD, Schmier JK, Lau EC, Shorr AF.

Cost Eff Resour Alloc. 2006 Oct 16;4:17.

Supplemental Content

Support Center